Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC

(RARE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations
Most relevant news about ULTRAGENYX PHARMACEUTICAL
02/21ULTRAGENYX PHARMACEUTICAL : Announces Positive 24-week Data from First Cohort of..
AQ
02/19ULTRAGENYX : 4Q Earnings Snapshot
AQ
02/19Ultragenyx Reports Fourth Quarter and Full Year 2018 Financial Results and Co..
GL
02/15Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita fro..
AQ
02/14ULTRAGENYX PHARMACEUTICAL : and Kyowa Kirin Announce Positive 64-Week Results fo..
AQ
02/12ULTRAGENYX PHARMACEUTICAL : to Host Conference Call for Fourth Quarter and Full-..
PU
02/12ULTRAGENYX PHARMACEUTICAL : to Host Conference Call for Fourth Quarter and Full-..
AQ
02/04Ultragenyx Appoints Shehnaaz Suliman, M.D., to Board of Directors
GL
01/22ULTRAGENYX PHARMACEUTICAL : Announces Positive Topline Data from Ongoing Long-Te..
AQ
01/07Flurry of management moves on eve of JPM
AQ
01/04Ultragenyx Announces Positive Topline Results from First Cohort of Phase 1/2 ..
GL
01/03Ultragenyx to Present at J.P. Morgan Healthcare Conference
GL
2018Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita™..
GL
2018ULTRAGENYX PHARMACEUTICAL : Announces Intent to Submit New Drug Application to U..
AQ
2018ULTRAGENYX PHARMACEUTICAL : to Present at Upcoming Investor Conferences
AQ
2018ULTRAGENYX PHARMACEUTICAL : to Present at Upcoming Investor Conferences
AQ
2018ULTRAGENYX : 3Q Earnings Snapshot
AQ
2018Ultragenyx Reports Third Quarter 2018 Financial Results and Corporate Update
GL
2018Lilly buys Siga's Priority Review voucher gained via smallpox approval
AQ
2018Ultragenyx to Host Conference Call for Third Quarter 2018 Financial Results a..
GL
2018ULTRAGENYX PHARMACEUTICAL : Announces Negative Topline Results from Phase 3 Stud..
AQ
2018ULTRAGENYX PHARMACEUTICAL : UX007 fails Phase III in glucose transporter disorde..
AQ
2018Ultragenyx Announces Negative Topline Results from Phase 3 Study of UX007 in ..
GL
2018ULTRAGENYX PHARMACEUTICAL : Announces Exclusive License to REGENXBIO AAV Vectors..
AQ
2018Ultragenyx Announces Exclusive License to REGENXBIO AAV Vectors to Develop Ge..
GL
2018ULTRAGENYX PHARMACEUTICAL : Announces Approval of Mepsevii in Brazil for the Tre..
AQ
2018Ultragenyx Announces Approval of Mepsevii™ (vestronidase alfa) in Brazi..
GL
2018FDA, EMA to review Novartis' siponimod for secondary progressive MS
AQ
2018ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy Summit
AQ
2018Ultragenyx Announces Positive Topline Cohort 2 Results from Phase 1/2 Clinica..
GL
2018ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy Summit
AQ
2018ULTRAGENYX PHARMACEUTICAL : Expands Leadership Team and Appoints Dr. Wladimir Ho..
AQ
2018Ultragenyx Expands Leadership Team and Appoints Dr. Wladimir Hogenhuis as Chi..
GL
2018Ultragenyx to Present at Upcoming Investor Conferences
GL
2018ULTRAGENYX PHARMACEUTICAL : FDA clarifies path to submission for Ultragenyx's ra..
AQ
2018ULTRAGENYX PHARMACEUTICAL : Announces FDA Accepts Proposal to Submit an NDA for ..
AQ
2018ULTRAGENYX PHARMACEUTICAL : Announces Approval of Mepsevii in Europe for the Tre..
AQ
2018Ultragenyx Announces Approval of Mepsevii™ (vestronidase alfa) in Europ..
GL
2018ULTRAGENYX : 2Q Earnings Snapshot
AQ
2018Ultragenyx Reports Second Quarter 2018 Financial Results and Corporate Update
GL
2018ULTRAGENYX PHARMACEUTICAL : to Host Conference Call for Second Quarter 2018 Fina..
AQ
2018Ultragenyx to Host Conference Call for Second Quarter 2018 Financial Results ..
GL
2018ULTRAGENYX PHARMACEUTICAL : Announces First Patient Dosed in Phase 1/2 study of ..
AQ
2018ULTRAGENYX PHARMACEUTICAL : Announces Positive CHMP Opinion for Mepsevii for the..
AQ
2018CHMP backs CAR Ts, Orphan candidates
AQ
2018Ultragenyx Announces Positive CHMP Opinion for Mepsevii™ (vestronidase ..
GL
2018ULTRAGENYX PHARMACEUTICAL : to Present at Upcoming Investor Conferences
AQ
2018Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demo..
AQ
2018Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demo..
GL
2018Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results
AQ
2018Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrati..
AQ
2018Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrati..
GL
2018Ultragenyx and Kyowa Kirin Announce Crysvita Now Launched in the U.S. for the..
AQ
2018ULTRAGENYX PHARMACEUTICAL : Reports First Quarter 2018 Financial Results and Cor..
AQ
2018ULTRAGENYX : 1Q Earnings Snapshot
AQ
2018Ultragenyx Reports First Quarter 2018 Financial Results and Corporate Update
GL
2018ULTRAGENYX PHARMACEUTICAL : to Host Conference Call for First Quarter 2018 Finan..
AQ
2018Ultragenyx and Kyowa Kirin Announce Crysvita Now Launched in the U.S. for the..
AQ
2018Ultragenyx to Host Conference Call for First Quarter 2018 Financial Results a..
GL
2018Ultragenyx and Kyowa Kirin Announce Crysvita® (burosumab-twza) Now Launched i..
GL
2018Ultragenyx Announces Filing and FDA Clearance of an Investigational New Drug ..
GL
2018Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita® (burosumab-twza..
GL
2018Ultragenyx to Present at Upcoming Investor Conferences
GL
2018ULTRAGENYX PHARMACEUTICAL : Announces Positive Topline Results and DMC Review fr..
AQ
2018Kyowa Kirin and Ultragenyx Announce Crysvita Receives Conditional Marketing A..
AQ
2018XLH therapy burosumab gains EU approval
AQ
2018Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditiona..
GL
2018Ultragenyx Reports Fourth Quarter and Full Year 2017 Financial Results and Co..
GL
2018ULTRAGENYX PHARMACEUTICAL : to Host Conference Call for Fourth Quarter and Full ..
PU
2018Ultragenyx to Host Conference Call for Fourth Quarter and Full Year 2017 Fin..
GL
2018Ultragenyx to Present at Leerink Partners Global Healthcare Conference
GL
2018Ultragenyx Appoints Camille L. Bedrosian, M.D. as Chief Medical Officer and E..
GL
2018Ultragenyx Announces Pricing of Public Offering of Common Stock
GL
2018Ultragenyx Announces Proposed Public Offering of Common Stock
GL
2018NEWMAN FERRARA LLP : Announces Corporate Governance Investigation of Ultragenyx ..
BU
1  2  3  4Next
Upcoming event on ULTRAGENYX PHARMACEUTICAL